世界中の市場調査レポートを販売!当社に無いレポートもお探しします。

レポートナンバー 0000029257

大うつ病性障害 − 2029年までの世界の医薬品予測と市場分析

GlobalData

Major Depressive Disorder - Global Drug Forecast and Market Analysis to 2029

発刊日 2021/03/31

言語英語

体裁PDF/120ページ

ライセンス/価格120ページ

0000029257

Single
Site
Global

※ご請求は、お申込日のTTSレートで円換算し、消費税を加えた金額になります。
※本レポートは、英文です。PDF(電子媒体)での納品となります。
※本レポートは取り寄せとなりますので、申し込みからお届けまで、多少時間が掛かる場合がございます。

無料サンプル

  • サンプルはお問い合わせください。

レポート概要

大うつ病性障害(MDD)は、世界的に最も多い精神疾患の一つであり、単一または再発性大うつ病エピソード(MDE)を特徴とします。MDDは、MDEが統合失調症、統合失調感情障害、統合失調症状障害、妄想性障害などの精神病性障害ではうまく説明できず、軽躁状態や躁状態の既往がない場合にのみ診断されます。単極性うつ病性障害という用語は、MDDを、双極性障害として知られる躁病エピソードに関連して発生するうつ病エピソードと区別するためによく使用されます。

MDD市場は混雑した競争の激しい市場であり、患者の治療に利用できる製品は数多くありますが、その大半は安価なジェネリック医薬品として提供されています。MDD市場の製品は、一般的に、SSRI、SNRI、その他の抗うつ薬、そして補助療法の4つの主要カテゴリーに分類されます。SSRIクラスの薬剤は、MDD治療のゴールドスタンダードと広く考えられており、抗うつ薬の中で最もよく使われています。

■ 調査範囲

  • 疫学、病因、病態生理、症状、診断、疾病管理などを含む大うつ病性障害の概要。
  • 大うつ病治療薬市場の収益、患者一人当たりの治療費、3つの患者セグメント(軽度、中等度、重度)における治療薬の使用パターンの2019年から2029年までの予測値。
  • 主要なトピックには、戦略的な競合他社の評価、市場の特性評価、アンメットニーズ、臨床試験のマッピング、および大うつ病性障害治療薬市場への影響が含まれます。
  • パイプライン分析:大うつ病性障害治療のために開発中の新たな傾向と作用機序を評価する包括的なデータ。開発のフェーズIIIで最も有望な候補がプロファイルされます。
  • 大うつ病性障害治療薬の世界市場における、現在および将来の市場競争の分析。業界の主要な推進要因、抑制要因、および課題についての洞察に満ちたレビュー。それぞれの動向は、その影響の定性分析を提供するために独立して調査されます。

レポート詳細

目次

Table of Contents

1 Major Depressive Disorder: Executive Summary
1.1 MDD Therapeutics Market Will Grow to $7.9B by 2029
1.2 Key Players Will Struggle to Maintain Their Competitive Position
1.3 Better Efficacy and Rapid Onset of Action Are the Most Pressing Unmet Needs in the MDD Market
1.4 Novel Late-Stage Pipeline Drugs Will Be a Key Driver of Growth
1.5 What Do Physicians Think?

2 Introduction
2.1 Catalyst
2.2 Related Reports
2.3 Upcoming Reports

3 Disease Overview
3.1 Etiology and Pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
3.2 Classification
3.3 Prognosis
3.4 Quality of Life

4 Epidemiology
4.1 Disease Background
4.2 Risk Factors and Comorbidities
4.3 Global and Historical Trends
4.4 Forecast Methodology
4.4.1 Sources Used
4.4.2 Sources Not Used
4.4.3 Forecast Assumptions and Methods
4.4.4 Forecast Assumptions and Methods: 12-Month Total Prevalence of MDD
4.4.5 Forecast Assumptions and Methods: 12-Month Total Prevalence of MDD by Severity
4.5 Epidemiological Forecast for MDD (2019-2029)
4.5.1 12-Month Total Prevalent Cases of MDD
4.5.2 Age-Specific 12-Month Total Prevalence of MDD
4.5.3 Sex-Specific 12-Month Prevalent Cases of MDD
4.5.4 12-Month Total Prevalent Cases of MDD by Severity for Ages <18 Years
4.6 Discussion
4.6.1 Epidemiological Forecast Insight
4.6.2 Coronavirus Disease 2019 (COVID-19) Impact
4.6.3 Limitations of Analysis
4.6.4 Strengths of Analysis

5 Disease Management
5.1 Diagnosis and Treatment Overview
5.2 KOL Insights on Disease Management

6 Competitive Assessment
6.1 Overview

7 Unmet Needs and Opportunity Assessment
7.1 Overview
7.2 Rapid Onset of Action
7.3 New Therapies with Better Efficacy
7.4 Improved Safety Profiles
7.5 Management of Patient Outcome Expectations

8 R&D Strategies
8.1 Overview
8.1.1 Novel MOAs
8.1.2 Development of Adjunctive Therapies
8.1.3 Digital Therapeutics
8.1.4 Personalized Treatments/Biomarkers
8.2 Clinical Trials Design
8.2.1 Study Design
8.2.2 Endpoints
8.2.3 Placebo Response Rates

9 Pipeline Assessment
9.1 Overview
9.2 Promising Drugs in Clinical Development
9.3 Other Drugs in Development

10 Pipeline Valuation Analysis
10.1 Overview
10.2 Competitive Assessment

11 Current and Future Players
11.1 Overview
11.2 Deal-Making Trends

12 Market Outlook
12.1 Global Markets
12.1.1 Forecast
12.1.2 Drivers and Barriers - Global Issues
12.2 US
12.2.1 Forecast
12.2.2 Key Events
12.2.3 Drivers and Barriers
12.3 5EU
12.3.1 Forecast
12.3.2 Key Events
12.3.3 Drivers and Barriers
12.4 Japan
12.4.1 Forecast
12.4.2 Key Events
12.4.3 Drivers and Barriers
12.5 Canada
12.5.1 Forecast
12.5.2 Key Events
12.5.3 Drivers and Barriers

13 Appendix

List of Tables
Table 1: Major Depressive Disorder: Key Metrics in the 8MM
Table 2: DSM-V Criteria of Major Depressive Episode
Table 3: ICD-10 Criteria of Major Depressive Episode
Table 4: Subtypes of Major Depressive Episode
Table 5: Risk Factors and Comorbidities for MDD
Table 6: Treatment Guidelines for Major Depressive Disorder
Table 7: Drugs in Development for Major Depressive Disorder, 2021
Table 8: MDD Market - Global Drivers and Barriers, 2019-2029
Table 9: Key Events Impacting Sales for MDD in the US, 2019-2029
Table 10: MDD Market - Drivers and Barriers in the US, 2019-2029
Table 11: Key Events Impacting Sales for MDD in the 5EU, 2019-2029
Table 12: MDD Market - Drivers and Barriers in the 5EU, 2019-2029
Table 13: Key Events Impacting Sales for MDD in Japan, 2019-2029
Table 14: MDD Market - Drivers and Barriers in Japan, 2019-2029
Table 15: Key Events Impacting Sales for MDD in Canada, 2019-2029
Table 16: MDD Market - Drivers and Barriers in Canada, 2019-2029
Table 17: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures
Figure 1: Global Sales Forecast by Country for MDD in 2019 and 2029
Figure 2: Analysis of the Company Portfolio Gap in MDD During the Forecast Period
Figure 3: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to Be Licensed for the Treatment of MDD During the Forecast Period
Figure 4: Overview of Targets of Antidepressant Action on Noradrenergic and Serotonergic Neurons
Figure 5: 8MM, 12-Month Total Prevalence of MDD (%), Men and Women, Ages ≥18 Years, 2019
Figure 6: 8MM, Sources Used and Not Used to Forecast the 12-Month Total Prevalent Cases of MDD
Figure 7: 8MM, Sources Used to Forecast the 12-Month Total Prevalent Cases of MDD, by Severity
Figure 8: 8MM, 12-Month Total Prevalent Cases of MDD, N, Both Sexes, Ages ≥18 Years, 2019
Figure 9: 8MM, 12-Month Total Prevalent Cases of MDD by Age, N, Both Sexes, 2019
Figure 10: 8MM, 12-Month Total Prevalent Cases of MDD by Sex, N, Ages ≥18 Years, 2019
Figure 11: 8MM, Total Prevalent Cases of MDD by Severity, N, Ages ≥18 Years, 2019
Figure 12: Disease Management Model for MDD
Figure 13: MDD Treatment Algorithm
Figure 14: Unmet Needs and Opportunities in MDD
Figure 15: Overview of the Development Pipeline in Major Depressive Disorder
Figure 16: Key Late-Stage Trials for the Promising Pipeline Agents that GlobalData Expects to Be Licensed for MDD in the 8MM During the Forecast Period
Figure 17: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to Be Licensed for the Treatment of MDD During the Forecast Period
Figure 18: Competitive Assessment of the Marketed and Pipeline Drug Monotherapies Benchmarked Against the Standard of Care (SOC), Lexapro
Figure 19: Competitive Assessment of the Marketed and Pipeline Drug Adjunctive Therapies Benchmarked Against the Standard of Care (SOC), Abilify
Figure 20: Analysis of the Company Portfolio Gap in MDD During the Forecast Period
Figure 21: Global (8MM) Sales Forecast by Country for MDD in 2019 and 2029
Figure 22: Global (8MM) Sales Forecast by Drug Class for MDD in 2019 and 2029
Figure 23: Sales Forecast by Class for MDD in the US in 2019 and 2029
Figure 24: 5EU Sales Forecast by Country for MDD in 2019 and 2029
Figure 25: 5EU Sales Forecast by Class for MDD in 2019 and 2029
Figure 26: Sales Forecast by Class for MDD in Japan in 2019 and 2029
Figure 27: Sales Forecast by Class for MDD in Canada in 2019 and 2029

この商品のレポートナンバー

0000029257

TOP